# GHK-Cu Copper Peptide Hair Growth Research | Clinic GHK-Cu > Randomized controlled trial data, follicle cycle biology, DHT interaction, and comparison with minoxidil. Every finding cited. **URL:** https://clinicghkcu.com/hair-growth **Canonical HTML:** https://clinicghkcu.com/hair-growth --- ## Hair Follicle Biology and GHK-Cu Hair follicle cycling — the sequential progression through anagen (growth), catagen (transition), and telogen (rest) phases — is regulated by a network of growth factors, androgens, and extracellular matrix signals. GHK-Cu interacts with this network at several nodes. The tripeptide has been shown to stimulate dermal papilla cells, which are the signaling hub for follicle cycling. In culture, GHK-Cu treatment increased dermal papilla cell viability and upregulated expression of growth factors including VEGF and TGF-beta1 — both associated with anagen phase maintenance. It also promoted proliferation of outer root sheath keratinocytes, which are the progenitor cells that regenerate the hair shaft. Source: Pickart L, Margolina A. International Journal of Molecular Sciences. 2018;19(7):1987. PMID: 29987235. --- ## Lee 2016 Randomized Controlled Trial The most cited clinical study on GHK-Cu and hair growth is Lee et al. (2016), published in the Annals of Dermatology. **Study design:** - Design: randomized, double-blind, placebo-controlled - Population: patients with androgenetic alopecia - Intervention: topical complex containing GHK-Cu and 5-aminolevulinic acid (ALA), applied twice daily for 12 weeks - Controls: placebo vehicle (twice daily) **Results:** - Treatment group: mean increase of **+71.5 hairs per cm²** from baseline (p < 0.001) - Placebo group: no statistically significant change - Secondary measures: increased hair shaft diameter and improved global photographic assessment scores in the treatment group - Adverse events: mild, transient scalp erythema in a minority of participants; no serious adverse events reported **Limitations:** The trial tested a combination product (GHK-Cu + 5-ALA), not isolated GHK-Cu. The individual contribution of each component cannot be separated from this study design alone. Source: Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Annals of Dermatology. 2016;28(4):438-443. PMID: 27489430. --- ## Timeline of Hair Effects Based on the available literature, in vitro and in vivo studies suggest the following approximate timeline of effects when GHK-Cu is present at biologically relevant concentrations: | Timeframe | Observed effects (research models) | |---|---| | 2–4 weeks | Dermal papilla cell viability increases; gene expression changes detectable | | 6–8 weeks | Anagen phase prolongation observed in animal models | | 12 weeks | Clinically significant hair density change reported in Lee 2016 RCT | | Beyond 12 weeks | No long-term human data available in the published literature | This timeline reflects research observations only. It is not a treatment protocol or guarantee. --- ## DHT Interaction Dihydrotestosterone (DHT) is the primary androgen implicated in androgenetic alopecia. It binds the androgen receptor in dermal papilla cells and triggers miniaturization of hair follicles over successive cycles. GHK-Cu has been found to modulate TGF-beta1 signaling in dermal papilla cells. TGF-beta1 is a downstream effector in DHT-induced follicle regression — and GHK-Cu appears to reduce its inhibitory effect on follicle cycling. The mechanism is not a direct androgen receptor antagonism but rather an interference with downstream signaling that partially offsets DHT-induced catagen acceleration. This does not constitute a DHT-blocking mechanism in the conventional pharmacological sense, and GHK-Cu is not classified or studied as a 5-alpha-reductase inhibitor. Source: Pickart L, Margolina A. International Journal of Molecular Sciences. 2018;19(7):1987. --- ## GHK-Cu vs. Minoxidil: Research Comparison | Feature | GHK-Cu | Minoxidil (2% or 5% topical) | |---|---|---| | Mechanism | Dermal papilla signaling, TGF-beta1 modulation | Potassium channel opening, VEGF upregulation | | RCT evidence | Lee 2016 (+71.5 hairs/cm², combination product) | Multiple RCTs (independent, isolated compound) | | Hair density increase | +71.5 hairs/cm² (12 weeks, combination) | Varies; typically +10–20 hairs/cm² in monotherapy RCTs | | DHT effect | Indirect signaling modulation | No direct DHT effect | | Tolerability | Mild scalp erythema in minority (Lee 2016) | Scalp irritation, initial shedding common | | Regulatory status | Cosmetic ingredient (INCI: Copper Tripeptide-1) | FDA-approved OTC drug (US) | **Important note:** The Lee 2016 trial used a combination product. Direct head-to-head comparison between isolated GHK-Cu and minoxidil does not exist in the current literature. --- ## Efficacy Summary The published evidence supports the following statements about GHK-Cu and hair growth: - A randomized controlled trial showed statistically significant improvement in hair density at 12 weeks with a topical GHK-Cu-containing product. - Mechanistic studies support biological plausibility through dermal papilla cell stimulation and TGF-beta1 modulation. - No published data compares isolated GHK-Cu monotherapy to minoxidil or finasteride in a head-to-head design. - No published long-term safety or efficacy data (beyond 12 weeks) exists for GHK-Cu hair applications in humans. --- ## Disclaimer For research purposes only. Not for human consumption. This site does not sell any product. A peer-reviewed reading room for the GHK-Cu literature — editorial summaries, not clinical guidance. © 2026 Clinic GHK-Cu. All content is editorial commentary on publicly available peer-reviewed research.